المؤلفون: Brismar, K, Benroubi, M, Nicolay, C, Schmitt, H, Giaconia, J, Reaney, M

المصدر: Journal of medical economics. 16(8):1022-35

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:223738910Test

المؤلفون: Oguz, A, Benroubi, M, Brismar, K, Melo, P, Morar, C, Cleall, SP, Giaconia, J, Schmitt, H

المصدر: Current medical research and opinion. 29(8):911-920

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:127081298Test

المؤلفون: Pirags, V., El Damassy, H., Dabrowski, M., Gönen, M. S., Racicka, E., Martinka, E., Giaconia, J., Stefanski A.

المساهمون: Selçuk Üniversitesi, Gönen, M. S.

الوصف: WOS: 000310265500005 ; PubMed: 23067027 ; Aims: The choice of insulin at initiation in type 2 diabetes remains controversial. The aim of this study was to assess the occurrence of self-reported severe hypoglycaemia associated with premixed insulin analogues in routine clinical care. Methods: A 12-month, prospective, observational, multicentre study in patients starting a commonly prescribed premixed insulin analogue (either insulin lispro 25/75 or biphasic insulin aspart 30/70, twice daily) after suboptimal glycaemic control on oral antidiabetic agents. Treatment decisions were made solely in the course of usual practice. Results: Study follow-up was completed by 991 (85.5%) of the 1150 patients enrolled. At baseline, mean (SD) age was 57.9 (10.1) years; mean diabetes duration was 9.2 (5.9) years; mean haemoglobin A1c (HbA1c) was 9.9 (1.8) % and the rate of severe hypoglycaemia was 0.03 episode/patient-year. At 12 months, the rate of severe hypoglycaemia was 0.04 episode/patient-year (95% CI 0.023, 0.055 episode/patient-year) and mean insulin dose was 41.5 (19.4) units. Changes from baseline to 12 months for mean fasting plasma glucose and HbA1c were -5.1 mmol/l and -2.5%, respectively. Conclusions: After initiation of premixed insulin analogues in patients with type 2 diabetes in real-world settings, the incidence of severe hypoglycaemia was lower than expected from previously reported studies. ; Eli Lilly and CompanyEli Lilly ; This study was supported by Eli Lilly and Company. The following employees of Eli Lilly and Company were involved: Jacek Kiljanski, MD, for study design; Helmut Petto, MSc, for study design, analysis planning and implementation; Matthew Reaney, MSc, for data interpretation and Simon Cleall, MSc, for data interpretation. The authors thank the study investigators, who are listed in the Appendix.

وصف الملف: application/pdf

العلاقة: International Journal of Clinical Practice; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Pirags, V., El Damassy, H., Dabrowski, M., Gonen, M. S., Racicka, E., Martinka, E., Giaconia, J., Stefanski A., (2012). Low Risk of Severe Hypoglycaemia in Patients With Type 2 Diabetes Mellitus Starting Insulin Therapy With Premixed Insulin Analogues Bid in Outpatient Settings. International Journal of Clinical Practice, 66(11), 1033-1041. Doi:10.1111/j.1742 1241.2012.03001.x; https://dx.doi.org/10.1111Test/j.1742-1241.2012.03001.x; https://hdl.handle.net/20.500.12395/28201Test; 66; 11; 1033; 1041

الإتاحة: https://doi.org/20.500.12395/28201Test
https://doi.org/10.1111Test/j.1742-1241.2012.03001.x
https://doi.org/10.1111Test/j.1742
https://hdl.handle.net/20.500.12395/28201Test

المؤلفون: Gonen, MUSTAFA SAİT, PIRAGS, V., EL DAMASSY, H., DABROWSKI, M., RACICKA, E., MARTINKA, E., GIACONIA, J., STEFANSKI, A.

المساهمون: University of Latvia ,, 104306

مصطلحات موضوعية: Yaşam Bilimleri (LIFE), TIP, GENEL & İÇECEK, Klinik Tıp, Klinik Tıp (MED), FARMAKOLOJİ VE ECZACILIK, Farmakoloji ve Toksikoloji, Tıp, Sağlık Bilimleri, Temel Tıp Bilimleri, Eczacılık, Temel Eczacılık Bilimleri, Yaşam Bilimleri, Temel Bilimler

الوصف: Aims: The choice of insulin at initiation in type 2 diabetes remains controversial. The aim of this study was to assess the occurrence of self-reported severe hypoglycaemia associated with premixed insulin analogues in routine clinical care. Methods: A 12-month, prospective, observational, multicentre study in patients starting a commonly prescribed premixed insulin analogue (either insulin lispro 25/75 or biphasic insulin aspart 30/70, twice daily) after suboptimal glycaemic control on oral antidiabetic agents. Treatment decisions were made solely in the course of usual practice. Results: Study follow-up was completed by 991 (85.5%) of the 1150 patients enrolled. At baseline, mean (SD) age was 57.9 (10.1) years; mean diabetes duration was 9.2 (5.9) years; mean haemoglobin A1c (HbA1c) was 9.9 (1.8) % and the rate of severe hypoglycaemia was 0.03 episode/patient-year. At 12 months, the rate of severe hypoglycaemia was 0.04 episode/patient-year (95% CI 0.023, 0.055 episode/patient-year) and mean insulin dose was 41.5 (19.4) units. Changes from baseline to 12 months for mean fasting plasma glucose and HbA1c were -5.1 mmol/l and -2.5%, respectively. Conclusions: After initiation of premixed insulin analogues in patients with type 2 diabetes in real-world settings, the incidence of severe hypoglycaemia was lower than expected from previously reported studies.

العلاقة: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE; PIRAGS V., EL DAMASSY H., DABROWSKI M., Gonen M. S. , RACICKA E., MARTINKA E., GIACONIA J., STEFANSKI A., "Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.66, sa.11, ss.1033-1041, 2012; av_4b7c1daf-a370-4167-acc5-13d68671cfc1; vv_1032021; http://hdl.handle.net/20.500.12627/54164Test; https://doi.org/10.1111Test/j.1742-1241.2012.03001.x; 66; 11; 1033; 1041

الإتاحة: https://doi.org/20.500.12627/54164Test
https://doi.org/10.1111Test/j.1742-1241.2012.03001.x
https://hdl.handle.net/20.500.12627/54164Test

المؤلفون: Chacra, A. R., Kipnes, M., Ilag, L. L., Sarwat, S., Giaconia, J., Chan, J.

المصدر: Diabetic Medicine ; volume 27, issue 5, page 563-569 ; ISSN 0742-3071 1464-5491

الوصف: Diabet. Med. 27, 563–569 (2010) Abstract Aims The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in basal‐bolus regimens in Type 1 diabetes. Methods In this 32‐week, multinational, parallel‐group, randomized, controlled trial, adult patients with Type 1 diabetes received ILPS or insulin detemir, injected twice daily (before breakfast and bedtime) and prandial insulin lispro three times daily. The primary outcome was change in glycated haemoglobin (HbA 1c ) from baseline to endpoint. Results Least squares mean (± se ) changes in HbA 1c were similar between groups, meeting non‐inferiority (margin, 0.4%): −0.69 ± 0.07% for ILPS and −0.59 ± 0.07% for insulin detemir [between‐treatment difference −0.10%; 95% confidence interval (CI) −0.29, 0.10]. Standard deviation of fasting blood glucose was similar (non‐inferiority margin 0.8 mmol/l): 2.74 ± 0.14 mmol/l for ILPS and 2.38 ± 0.14 mmol/l for insulin detemir (CI −0.03, 0.75). Patients on ILPS gained more weight (1.59 ± 0.23 kg vs. 0.62 ± 0.24 kg; CI 0.34, 1.60; margin 1.5 kg). Weight‐adjusted daily total and prandial insulin doses were lower for ILPS (prandial insulin, 0.38 ± 0.01 U/kg/day for ILPS, 0.44 ± 0.01 U/kg/day for insulin detemir; P = 0.004); daily basal insulin dose was similar. All hypoglycaemia incidence and rate and nocturnal hypoglycaemia incidence were similar between groups; nocturnal hypoglycaemia rate was lower for insulin detemir (mean ± sd 0.79 ± 1.23 for ILPS, 0.49 ± 0.85 for insulin detemir; P = 0.001). Severe hypoglycaemia rate was 0.03 ± 0.11 for ILPS and 0.02 ± 0.10 for insulin detemir ( P = 0.37). Conclusions ILPS‐treated patients with Type 1 diabetes achieved similar glycaemic control as insulin detemir‐treated patients after 32 weeks. Glucose variability was similar. While weight gain and nocturnal hypoglycaemia rate were statistically higher with ILPS, the clinical relevance is unclear.

الإتاحة: https://doi.org/10.1111Test/j.1464-5491.2010.02986.x

المؤلفون: Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., Pretlow, T. P.

المصدر: JNCI Journal of the National Cancer Institute ; volume 85, issue 5, page 394-398 ; ISSN 0027-8874 1460-2105

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1093/jnci/85.5.394Test
http://academic.oup.com/jnci/article-pdf/85/5/394/7807428/85-5-394.pdfTest